Driving Our Science Forward to the Clinic

We are developing therapeutics with the potential to reverse and prevent multiple aging-related diseases, each with critical unmet medical needs.

Life Bio is rapidly advancing its therapeutic pipeline of first-in-class treatments across organ systems starting with ocular indications. A number of other therapies for age-related diseases are currently under development.

Our Lead Candidate: ER-100

Life Bio’s lead program is a gene therapy called ER-100,which allows for expression of three transcription factors, Oct-4, Sox-2, and Klf-4 (“OSK”), which induces partial epigenetic reprogramming to modify the epigenome of cells. We are evaluating ER-100 in two optic neuropathies, non-arteritic anterior ischemic optic neuropathy (NAION) and primary open angle glaucoma (POAG), with plans to initiate the first human clinical studies in the second half of 2025.

Additional Indications

We are exploring the potential of our partial epigenetic reprogramming platform in additional age-related indications. Each additional indication pursued is based on evidence of epigenetic changes in an age-related disease that impacts healthspan.

We are rapidly developing appropriate delivery systems to enable OSK expression for these organ systems, demonstrating proof of concept in appropriate animal models, and identifying/advancing lead candidates.